Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):863-9. doi: 10.1002/eji.201041225.

2.
3.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

4.

Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.

Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A.

PLoS One. 2012;7(1):e30898. doi: 10.1371/journal.pone.0030898. Epub 2012 Jan 27.

5.

Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic.

López-Macías C.

Hum Vaccin Immunother. 2012 Mar;8(3):411-4. doi: 10.4161/hv.18757. Epub 2012 Feb 14. Review.

6.

Effect of prednisone on response to influenza virus vaccine in asthmatic children.

Fairchok MP, Trementozzi DP, Carter PS, Regnery HL, Carter ER.

Arch Pediatr Adolesc Med. 1998 Dec;152(12):1191-5.

PMID:
9856428
7.

Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).

Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y.

J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7.

PMID:
22872731
8.
9.

Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.

Staneková Z, Varečková E.

Virol J. 2010 Nov 30;7:351. doi: 10.1186/1743-422X-7-351. Review.

10.

Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Tan M, Jiang X.

Nanomedicine (Lond). 2012 Jun;7(6):889-97. doi: 10.2217/nnm.12.62. Review.

11.

Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine.

Cowling BJ, Fang VJ, Nishiura H, Chan KH, Ng S, Ip DK, Chiu SS, Leung GM, Peiris JS.

Clin Infect Dis. 2012 Jun;54(12):1778-83. doi: 10.1093/cid/cis307. Epub 2012 Mar 15.

12.

Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.

WHO Writing Group, Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Zhang W.

Influenza Other Respir Viruses. 2012 Mar;6(2):142-52, e1-5. doi: 10.1111/j.1750-2659.2011.00277.x. Epub 2011 Aug 8.

13.

Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design.

Ng AK, Zhang H, Tan K, Li Z, Liu JH, Chan PK, Li SM, Chan WY, Au SW, Joachimiak A, Walz T, Wang JH, Shaw PC.

FASEB J. 2008 Oct;22(10):3638-47. doi: 10.1096/fj.08-112110. Epub 2008 Jul 9.

14.

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H.

J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.

15.

Toward a universal influenza virus vaccine: prospects and challenges.

Pica N, Palese P.

Annu Rev Med. 2013;64:189-202. doi: 10.1146/annurev-med-120611-145115. Review.

PMID:
23327522
16.
17.

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.

J Virol. 2005 Mar;79(5):2910-9.

18.

Mucosal IgA responses in influenza virus infections; thoughts for vaccine design.

van Riet E, Ainai A, Suzuki T, Hasegawa H.

Vaccine. 2012 Aug 31;30(40):5893-900. doi: 10.1016/j.vaccine.2012.04.109. Epub 2012 Jul 24. Review.

PMID:
22835738
19.

Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.

Ravin NV, Kotlyarov RY, Mardanova ES, Kuprianov VV, Migunov AI, Stepanova LA, Tsybalova LM, Kiselev OI, Skryabin KG.

Biochemistry (Mosc). 2012 Jan;77(1):33-40. doi: 10.1134/S000629791201004X.

PMID:
22339631
20.

Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design.

Ichinohe T.

Expert Rev Vaccines. 2010 Nov;9(11):1315-24. doi: 10.1586/erv.10.118. Review.

PMID:
21087109

Supplemental Content

Support Center